FI3947392T3 - Isotiatsolidiini-1,1-dioksidia ja 1,4-butaanisultonia sisältäviä rapamysiinijohdannaisia ja niiden käyttöjä - Google Patents
Isotiatsolidiini-1,1-dioksidia ja 1,4-butaanisultonia sisältäviä rapamysiinijohdannaisia ja niiden käyttöjä Download PDFInfo
- Publication number
- FI3947392T3 FI3947392T3 FIEP20717312.1T FI20717312T FI3947392T3 FI 3947392 T3 FI3947392 T3 FI 3947392T3 FI 20717312 T FI20717312 T FI 20717312T FI 3947392 T3 FI3947392 T3 FI 3947392T3
- Authority
- FI
- Finland
- Prior art keywords
- cancer
- disease
- disorder
- liver
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824190P | 2019-03-26 | 2019-03-26 | |
| PCT/IB2020/052825 WO2020194209A1 (en) | 2019-03-26 | 2020-03-25 | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3947392T3 true FI3947392T3 (fi) | 2024-05-08 |
Family
ID=70190042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20717312.1T FI3947392T3 (fi) | 2019-03-26 | 2020-03-25 | Isotiatsolidiini-1,1-dioksidia ja 1,4-butaanisultonia sisältäviä rapamysiinijohdannaisia ja niiden käyttöjä |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220202787A1 (https=) |
| EP (1) | EP3947392B1 (https=) |
| JP (1) | JP7461369B2 (https=) |
| KR (1) | KR20210142689A (https=) |
| CN (1) | CN113614090B (https=) |
| AU (1) | AU2020250026B2 (https=) |
| BR (1) | BR112021018692A2 (https=) |
| CA (1) | CA3134653A1 (https=) |
| DK (1) | DK3947392T3 (https=) |
| ES (1) | ES2987625T3 (https=) |
| FI (1) | FI3947392T3 (https=) |
| HR (1) | HRP20240633T1 (https=) |
| HU (1) | HUE067396T2 (https=) |
| LT (1) | LT3947392T (https=) |
| MX (1) | MX2021011376A (https=) |
| PL (1) | PL3947392T3 (https=) |
| PT (1) | PT3947392T (https=) |
| RS (1) | RS65531B1 (https=) |
| SI (1) | SI3947392T1 (https=) |
| WO (1) | WO2020194209A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| HRP20250197T1 (hr) | 2018-12-18 | 2025-04-11 | Novartis Ag | Derivati rapamicina |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| JP2023028473A (ja) * | 2021-08-19 | 2023-03-03 | 日本マイクロバイオファーマ株式会社 | エベロリムスの製造方法 |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| CA2257803C (en) * | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| ATE264863T1 (de) * | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| AR112834A1 (es) * | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
-
2020
- 2020-03-25 US US17/442,733 patent/US20220202787A1/en active Pending
- 2020-03-25 RS RS20240515A patent/RS65531B1/sr unknown
- 2020-03-25 JP JP2021557231A patent/JP7461369B2/ja active Active
- 2020-03-25 FI FIEP20717312.1T patent/FI3947392T3/fi active
- 2020-03-25 HU HUE20717312A patent/HUE067396T2/hu unknown
- 2020-03-25 MX MX2021011376A patent/MX2021011376A/es unknown
- 2020-03-25 WO PCT/IB2020/052825 patent/WO2020194209A1/en not_active Ceased
- 2020-03-25 CA CA3134653A patent/CA3134653A1/en active Pending
- 2020-03-25 KR KR1020217033691A patent/KR20210142689A/ko active Pending
- 2020-03-25 PL PL20717312.1T patent/PL3947392T3/pl unknown
- 2020-03-25 SI SI202030428T patent/SI3947392T1/sl unknown
- 2020-03-25 CN CN202080022154.4A patent/CN113614090B/zh active Active
- 2020-03-25 BR BR112021018692A patent/BR112021018692A2/pt unknown
- 2020-03-25 PT PT207173121T patent/PT3947392T/pt unknown
- 2020-03-25 EP EP20717312.1A patent/EP3947392B1/en active Active
- 2020-03-25 ES ES20717312T patent/ES2987625T3/es active Active
- 2020-03-25 HR HRP20240633TT patent/HRP20240633T1/hr unknown
- 2020-03-25 LT LTEPPCT/IB2020/052825T patent/LT3947392T/lt unknown
- 2020-03-25 AU AU2020250026A patent/AU2020250026B2/en active Active
- 2020-03-25 DK DK20717312.1T patent/DK3947392T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7461369B2 (ja) | 2024-04-03 |
| MX2021011376A (es) | 2021-10-13 |
| KR20210142689A (ko) | 2021-11-25 |
| EP3947392B1 (en) | 2024-02-28 |
| CN113614090A (zh) | 2021-11-05 |
| RS65531B1 (sr) | 2024-06-28 |
| SI3947392T1 (sl) | 2024-07-31 |
| EP3947392A1 (en) | 2022-02-09 |
| HUE067396T2 (hu) | 2024-10-28 |
| PT3947392T (pt) | 2024-05-14 |
| AU2020250026B2 (en) | 2023-08-10 |
| AU2020250026A1 (en) | 2021-09-23 |
| LT3947392T (lt) | 2024-05-27 |
| BR112021018692A2 (pt) | 2021-11-23 |
| WO2020194209A1 (en) | 2020-10-01 |
| JP2022527270A (ja) | 2022-06-01 |
| US20220202787A1 (en) | 2022-06-30 |
| HRP20240633T1 (hr) | 2024-08-02 |
| CA3134653A1 (en) | 2020-10-01 |
| PL3947392T3 (pl) | 2024-07-15 |
| CN113614090B (zh) | 2026-04-28 |
| ES2987625T3 (es) | 2024-11-15 |
| DK3947392T3 (da) | 2024-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3947392T3 (fi) | Isotiatsolidiini-1,1-dioksidia ja 1,4-butaanisultonia sisältäviä rapamysiinijohdannaisia ja niiden käyttöjä | |
| HRP20240199T1 (hr) | Derivati rapamicina | |
| Altıntop et al. | A novel series of thiazolyl–pyrazoline derivatives: Synthesis and evaluation of antifungal activity, cytotoxicity and genotoxicity | |
| JP5701308B2 (ja) | 新規血管漏出遮断剤 | |
| EP4606427A3 (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| JP6311097B2 (ja) | 微小管脱重合剤 | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| Sabir et al. | Novel quinazolinone disulfide analogues as pqs quorum sensing inhibitors against Pseudomonas aeruginosa | |
| BR112021024439A2 (pt) | 9-hidroxi-1,8-dioxo-1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina-7-carboxamidas aneladas como inibidores de hiv integrase, métodos de preparação e aplicação dos mesmos | |
| JP2022514254A5 (https=) | ||
| JP2022527270A5 (https=) | ||
| AU2015360583A1 (en) | Small molecule inhibitors of fibrosis | |
| US20200331865A1 (en) | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | |
| EA201300826A1 (ru) | Применение димирацетама для лечения остеоартрита и связанных с ним заболеваний | |
| Inoue et al. | Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: Part 2 | |
| RU2006122637A (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| DK1732534T3 (da) | Anvendelse af methylenamidderivater ved cardiovaskulære sygdomme | |
| EA201171410A1 (ru) | Ингибиторы 11-бета-гидроксистероидной дегидрогеназы типа 1 | |
| JP2016502539A (ja) | 心臓疾患の予防又は治療用組成物 | |
| US20200157048A1 (en) | (2e,4e)-5-phenyl-penta-2,4-dien-1-one derivative | |
| MX2025001111A (es) | Nuevas sulfonamidas y su uso como agentes neuroprotectores y/o neurorrestauradores | |
| RU2021130616A (ru) | Производные рапамицина, содержащие изотиазолидин-1,1-диоксид и 1,4-бутансультон, и пути их применения | |
| EA200970422A1 (ru) | Аналоги пиразола | |
| US9303019B2 (en) | Amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome | |
| RU2021120838A (ru) | Производные рапамицина |